$VYGR

Voyager Therapeutics, Inc.

Voyager Therapeutics is a biotechnology company developing genetic medicines and other therapies for neurological diseases, including Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease and other central nervous system conditions. Its wholly owned pipeline includes VY1706, an intravenous tau-silencing gene therapy for Alzheimer’s, and VY7523, an anti-tau antibody. Voyager also has an early research program using its non-viral Voyager NeuroShuttle delivery platform. Its TRACER platform discovers adeno-associated virus capsids designed to deliver gene therapies across the blood-brain barrier. Voyager advances additional programs with collaborators, including gene therapy programs for Friedreich’s ataxia, Gaucher disease and Parkinson’s disease, and programs involving spinal muscular atrophy, Huntington’s disease and other neurological targets. It earns money through collaboration and licensing arrangements, which include upfront, milestone and license payments, research cost reimbursement and royalties. Voyager is headquartered in Lexington, Massachusetts.

No enriched coverage for $VYGR in the last 7 days.

No SEC Form 4 filings for $VYGR in the last 30 days.

See all $VYGR insider activity →

Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary

Voyager Therapeutics reported 3Q 2026 revenue of $4.01M, down 70% YoY, with a net loss of $24.69M, an 11.5% improvement. Collaboration revenue included $3.1M from Novartis and $0.5M from Neurocrine. The company reduced R&D and administrative expenses, extending its cash runway to Q2 2028.

Voyager Therapeutics, Inc. (VYGR): Completion of Acquisition or Disposition of Assets

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Voyager Reports Third Quarter 2026 Financial and Operating Results - VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to en

VYGR sentiment & insider activity

Recent VYGR coverage spans financial news, corporate actions and earnings.

What's driving VYGR

AlphAI scores every news story that mentions VYGR with an AI model for sentiment and relevance, and aggregates insider trades from Voyager Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VYGR

Score
$VYGRMedEarnings

Voyager Therapeutics, Inc. (VYGR): Completion of Acquisition or Disposition of Assets

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Voyager Reports Third Quarter 2026 Financial and Operating Results - VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to en

Voyager CEO on space death, why Mars matters, and how to fix data centers 500 miles up

Voyager Technologies CEO Dylan Taylor discusses the financial pressures on the space industry, similar to those in AI. He highlights the importance of a strong balance sheet for companies to compete. Voyager, a publicly traded company, recently raised $400 million. Taylor also mentions the interconnectedness of space and AI industries, their economic impact, and the potential for space-based data centers.

$VYGRLowExec change· appointed

Voyager Therapeutics, Inc. (VYGR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Robin Swartz On October 20, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Voyager The

Related tickers